对于 Lactobacillus acidophilus 的直接抑制作用,这是一种开始性尿路细菌,对氧酸盐石头的发展有直接的抑制作用
Chadanat Noonin1, Anantaya Putpim1,2, Visith Thongboonkerd3
1Medical Proteomics Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Microbiome
|September 17, 2024
概括
乳酸菌酸菌通过减少晶体形成,生长和粘附来抑制氧化 (CaOx) 石头的发展. 然而,大肠杆菌通过增强晶体生长和聚合促进了CaOx石头的形成.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 微生物学 微生物学
- 生物化学 生物化学
背景情况:
- 尿路细菌Lactobacillus acidophilus在健康人群中更为普遍,这表明它在预防结石疾病 (KSD) 中起着作用.
- 目前尚不清楚L. acidophilus如何影响酸盐 (CaOx) 石块形成的确切机制.
- 众所周知,大肠杆菌可促进CaOx结石的形成,提供了一个比较模型.
研究的目的:
- 研究L. acidophilus对CaOx石头发育的直接影响.
- 为了比较L. acidophilus与大肠杆菌对CaOx石质形成的影响.
- 阐明这些细菌对CaOx结晶和聚合的差异影响的机制.
主要方法:
- 评估L. acidophilus和E. coli对晶体形成,生长,聚合和粘附在体外对细胞的影响.
- 进行酸盐消耗测试,以评估细菌降解酸盐的能力.
- 分析表面成分,特别是L. acidophilus中的S层蛋白和E. coli中的鞭毛,以及它们在观察到的影响中的作用.
主要成果:
- L. acidophilus显著降低了CaOx晶体的形成,扩大,聚合和对细胞的粘附.
- 大肠杆菌显著增强了CaOx晶体的生长和聚合,但没有影响结晶或细胞粘附.
- 两种细菌都没有显著降低氧沙酸盐水平,这表明它们的作用并非主要是由于氧沙酸盐的降解. 两者都附着在CaOx晶体上,L. acidophilus表达S层蛋白质,而大肠杆菌表现出鞭毛.
结论:
- L. acidophilus通过干扰结晶,生长,聚合和细胞粘附来抑制CaOx石块的发展.
- 大肠杆菌通过增强晶体生长和聚合来促进CaOx石头的发展.
- 相反的效应归因于不同的表面成分 (S层蛋白与鞭毛),而不是氧酸盐降解.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
332
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
332
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
361
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
361
Antihypertensive Drugs: Action of Calcium Channel Blockers
471
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
471
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
410
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
410
Drugs for Treatment of Constipation-Predominant IBS
143
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
143
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
357
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
357


